Background The aim of this proof of concept, prospective, randomized pilot trial was to
investigate the effects of extracorporeal cytokine removal (CytoSorb®) applied as a
standalone treatment in patients with septic shock. Methods 20 patients with early (< 24 h)
onset of septic shock of medical origin, on mechanical ventilation, norepinephrine> 10
μg/min, procalcitonin (PCT)> 3 ng/mL without the need for renal replacement therapy were
randomized into CytoSorb (n= 10) and Control groups (n= 10). CytoSorb therapy lasted for …